GLP-1R agonists (GLP-1RAs), such as exenatide, liraglutide, albiglutide, dulaglutide, and recently semaglutide, approved for the treatment of type 2 diabesity and obesity, have become a promising pharmacological tool for reducing food intake and body weight [53,54] and new as yet unrecognized therapeutic indications could be developed. The gene discussed is GLP1R; the disease is Obesity.